Companies Shifting Focus to Better COVID-19 Testing
In order to meet the worldwide need for faster and affordable testing processes, companies must shift goals and apply resources to ending this pandemic.
Tag Archives: COVID-19
Asian Governments, Private Sector Response to Pandemic Shows Opportunity, Challenge
In general, the Asian markets have controlled the COVID-19 virus successfully outside of China, but its effect has still led to new developments and trends.
Shipments of COVID-19 Diagnostic Tests Top 1 Million Daily
AdvaMed’s Diagnostic Supply Registry is tracking the progress of molecular diagnostic tests to help support state and federal governments.
LabCorp Wins Reissued EUA for COVID-19 Test, First to Test Asymptomatic Population
The authorization is a step toward broad screening that will help reopen schools and workplaces in America, says FDA Commissioner Stephen Hahn, M.D.
How COVID-19 May Be the Catalyst in Ensuring a Healthy Future for Telemedicine
With everything to gain, telehealth may lead to a new standard in health/wellness treatment while at the same time unifying the entire healthcare ecosystem.
Tech Q&A: Artificial Intelligence Has Promise of Streamlining Hospital Processes, Diagnostic Tools
Companies developing technologies that integrate AI need to consider regulatory concerns, community demographics, fitting into existing workflows, technical proficiency of both the hospital personnel and consumers.
Post-COVID Era of Product Safety: Recall Risks During and After a Pandemic
The medical device industry is pressured to aid those stricken by the pandemic, while at the same time working to mitigate increased risks usually associated with hurried manufacturing and quality control procedures.
Pediatric Medical Devices Address COVID-19, 16 Companies Compete for Grants
The winning innovators will receive grant awards of upwards of $50,000.
Playing by the Rules: A Lever for Doing Better Business?
Investments in new processes and systems must satisfy the needs of the authorities and ensure patient safety and public confidence. Getting it right is likely to be expensive. but regulatory compliance shouldn’t be viewed purely as a cost center.
Full Economic Impact of COVID-19 on Life Sciences Industry Still Uncertain
While companies developing solutions that address the current pandemic may be receiving an influx of financial support, recovery for companies in other segments of the industry is slow.
